DCGI Flags Quality Of Medicines As Ongoing Concern In India
Apr 9, 2025


Source: Economic Times
Share:
The Drugs Controller General of India (DCGI) has raised concerns over the quality of medicines in the country, stating that improving drug standards remains a core focus for patient welfare. The remarks were made during the 3rd International Patients' Union Conference held recently in New Delhi.
Key Highlights
Quality Concerns in India’s Pharma Landscape
DCGI emphasized that ensuring the quality of medicines remains a “significant concern” in India.
The Central Drugs Standard Control Organization (CDSCO) is actively working to improve the regulatory framework to address this issue.
Patient Welfare at the Core
DCGI stated that patient welfare is central to CDSCO’s mission as it seeks to strengthen medicine quality and safety protocols.
Ongoing reforms aim to ensure higher accountability and better clinical outcomes.
Healthcare System Facing Long COVID Threat
Dr. K. Madan Gopal, Advisor, Public Health Administration (MoHFW), warned that if the long-term impacts of COVID-19 are not tackled, India risks losing its demographic dividend.
He stressed the need for stronger preventive and recovery-oriented healthcare systems.
Policy Vision from NITI Aayog
Dr. VK Paul of NITI Aayog highlighted India’s journey towards a patient-centric, high-quality health system.
Emphasized a balanced approach combining affordability, access, treatment, prevention, and rehabilitation.
Launch of Patient-Centric Fellowship Programme
The International Patients' Union, founded by Dr. Rajendra Pratap Gupta, announced a new fellowship programme in collaboration with IIM Raipur.
Fellows will engage directly with patients to develop policy recommendations for submission to NITI Aayog.
As the Indian pharmaceutical industry continues to scale globally, domestic quality concerns pose a serious challenge. For retail pharmacists, this underlines the importance of sourcing from compliant, licensed manufacturers and maintaining strict documentation and procurement standards. The industry’s path to trust and global recognition lies in robust quality assurance and patient-first practices.
Copyright © 2024 Pharmacy Pro. All rights reserved
Copyright © 2024 Pharmacy Pro. All rights reserved
Copyright © 2024 Pharmacy Pro. All rights reserved


Source: Economic Times
The Drugs Controller General of India (DCGI) has raised concerns over the quality of medicines in the country, stating that improving drug standards remains a core focus for patient welfare. The remarks were made during the 3rd International Patients' Union Conference held recently in New Delhi.
Key Highlights
Quality Concerns in India’s Pharma Landscape
DCGI emphasized that ensuring the quality of medicines remains a “significant concern” in India.
The Central Drugs Standard Control Organization (CDSCO) is actively working to improve the regulatory framework to address this issue.
Patient Welfare at the Core
DCGI stated that patient welfare is central to CDSCO’s mission as it seeks to strengthen medicine quality and safety protocols.
Ongoing reforms aim to ensure higher accountability and better clinical outcomes.
Healthcare System Facing Long COVID Threat
Dr. K. Madan Gopal, Advisor, Public Health Administration (MoHFW), warned that if the long-term impacts of COVID-19 are not tackled, India risks losing its demographic dividend.
He stressed the need for stronger preventive and recovery-oriented healthcare systems.
Policy Vision from NITI Aayog
Dr. VK Paul of NITI Aayog highlighted India’s journey towards a patient-centric, high-quality health system.
Emphasized a balanced approach combining affordability, access, treatment, prevention, and rehabilitation.
Launch of Patient-Centric Fellowship Programme
The International Patients' Union, founded by Dr. Rajendra Pratap Gupta, announced a new fellowship programme in collaboration with IIM Raipur.
Fellows will engage directly with patients to develop policy recommendations for submission to NITI Aayog.
As the Indian pharmaceutical industry continues to scale globally, domestic quality concerns pose a serious challenge. For retail pharmacists, this underlines the importance of sourcing from compliant, licensed manufacturers and maintaining strict documentation and procurement standards. The industry’s path to trust and global recognition lies in robust quality assurance and patient-first practices.
Share:
Read Next
Read Next
Copyright © 2024 Pharmacy Pro. All rights reserved
Copyright © 2024 Pharmacy Pro. All rights reserved